Key result
Lead compound 35, a novel 1,2,3,4-tetrahydroisoquinoline derivative, exhibited potent anti-influenza virus effects with EC50 values ranging from 0.43 to 1.12 μM in vitro.
Why the study?
Influenza PAN inhibitors are important to develop as a new generation of antiviral drugs due to the emergence of highly pathogenic influenza viruses and resistance to existing antiviral inhibitors.
Compound 35, a novel 1,2,3,4-tetrahydroisoquinoline-6,7-diol-based derivative, demonstrates potent in vitro and in vivo anti-influenza activity by inhibiting the PAN endonuclease.
Answers are grounded in this paper and cite their sources.
Novel PA N inhibitors show in vitro promise; leaves open clinical translation pending animal and human studies.
Influenza PA N inhibitors are of particular importance in current efforts to develop a new generation of antiviral drugs due to the growing emergence of highly pathogenic influenza viruses and the resistance to existing antiviral inhibitors. Herein, we design and synthesize a set of 1,3-cis- N -substituted-1,2,3,4-tetrahydroisoquinoline derivatives to enhance their potency by further exploiting the pockets 3 and 4 in the PA N endonuclease based on the hit d, l -laudanosoline. Particularly, the lead compound 35 exhibited potent and broad anti-influenza virus effects with EC 50 values ranging from 0.43 to 1.12 μM in vitro and good inhibitory activity in a mouse model. Mechanistic studies demonstrated that 35 could bind tightly to the PA N endonuclease of RNA-dependent RNA polymerase, thus blocking the viral replication to exert antiviral activity. Overall, our study might establish the importance of 1,2,3,4-tetrahydroisoquinoline-6,7-diol-based derivatives for the development of novel PA N inhibitors of influenza viruses.
No takes yet. Share an insight, caveat, or question.
Liao et al. (2022) studied Influenza. 1,3-cis-N-substituted-1,2,3,4-tetrahydroisoquinoline derivatives (lead compound 35) was evaluated on Anti-influenza virus effects (EC50) (EC50 0.43 to 1.12 μM). Lead compound 35, a novel 1,2,3,4-tetrahydroisoquinoline derivative, exhibited potent anti-influenza virus effects with EC50 values ranging from 0.43 to 1.12 μM in vitro.
Synapse has enriched 10 related papers. Consider them for comparative context: